# SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

> **NCT03113643** · PHASE1 · RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 72 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndrome
- Blastic Plasmacytoid Dendritic Cell Neoplasm

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** SL-401
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03113643
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-06-26
- **Primary completion:** 2026-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-11-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03113643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03113643, "SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03113643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*